Rituxan rituximab: Phase III data; marketed to treat low-grade NHL

Interim data from 328 previously untreated patients with aggressive NHL in IDPH's 400-patient Phase III

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE